GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » EV-to-FCF

GlaxoSmithKline Pakistan (KAR:GLAXO) EV-to-FCF : 29.56 (As of Mar. 31, 2025)


View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GlaxoSmithKline Pakistan's Enterprise Value is ₨126,731 Mil. GlaxoSmithKline Pakistan's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was ₨4,288 Mil. Therefore, GlaxoSmithKline Pakistan's EV-to-FCF for today is 29.56.

The historical rank and industry rank for GlaxoSmithKline Pakistan's EV-to-FCF or its related term are showing as below:

KAR:GLAXO' s EV-to-FCF Range Over the Past 10 Years
Min: -452.63   Med: 19.87   Max: 132.31
Current: 29.56

During the past 13 years, the highest EV-to-FCF of GlaxoSmithKline Pakistan was 132.31. The lowest was -452.63. And the median was 19.87.

KAR:GLAXO's EV-to-FCF is ranked worse than
58.47% of 549 companies
in the Drug Manufacturers industry
Industry Median: 23.45 vs KAR:GLAXO: 29.56

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-31), GlaxoSmithKline Pakistan's stock price is ₨418.43. GlaxoSmithKline Pakistan's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₨14.160. Therefore, GlaxoSmithKline Pakistan's PE Ratio (TTM) for today is 29.55.


GlaxoSmithKline Pakistan EV-to-FCF Historical Data

The historical data trend for GlaxoSmithKline Pakistan's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan EV-to-FCF Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.67 11.86 9.45 -4.95 -423.57

GlaxoSmithKline Pakistan Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.50 -423.57 11.51 9.04 12.77

Competitive Comparison of GlaxoSmithKline Pakistan's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pakistan's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's EV-to-FCF falls into.


;
;

GlaxoSmithKline Pakistan EV-to-FCF Calculation

GlaxoSmithKline Pakistan's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=126731.239/4287.759
=29.56

GlaxoSmithKline Pakistan's current Enterprise Value is ₨126,731 Mil.
GlaxoSmithKline Pakistan's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨4,288 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Pakistan  (KAR:GLAXO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

GlaxoSmithKline Pakistan's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=418.43/14.160
=29.55

GlaxoSmithKline Pakistan's share price for today is ₨418.43.
GlaxoSmithKline Pakistan's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨14.160.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


GlaxoSmithKline Pakistan EV-to-FCF Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pakistan Business Description

Traded in Other Exchanges
N/A
Address
35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in research, development, and manufacturing pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines